Alzheimer’s LINX™️Ultimately, Alzheimer’s LINX™ offers a crucial ability to treat AD even before the onset of symptoms, and before any neural damage has taken place, representing a revolution in AD diagnosis & care.
“Trust me… YOU WANT TO KNOW IF YOU ARE HEADED FOR TROUBLE! This way, we can help you change course and avoid disaster.”
~ Studio team
What is Alzheimer’s Disease?
Around a 5.5million Americans suffer from dementia caused by the onset of Alzheimer’s Disease (AD). AD, an irreversible, degenerative, progressive brain disorder, represents the most common cause of dementia (a general term applied to an impaired ability to think, remember, and make decisions) and is currently ranked as the sixth leading cause of death in the US. Symptoms generally appear in the mid-60’s age group, although it is thought, for many patients, that the progression of the disease might have begun to develop & then remain undetected for many years prior. Women are more at risk of contracting Alzheimer’s Disease than men, with recent research indicating that they also appear to suffer a greater cognitive deterioration than men over the course of the disease. However, that does not mean that men can afford to be complacent; in 2020, an estimated 5.8 million Americans had dementia, a number that is set to triple by 2060. Furthermore, while the lifetime risk of Alzheimer’s Disease is higher for women (two-thirds of Alzheimer sufferers are female), women are more likely to outlive men when they contract it.
Alzheimer’s LINX™: A Game Changer in Early Diagnosis
Medical consensus remains clear that early diagnosis of AD remains critical, yet orthodox testing does not facilitate such a goal. This is where Alzheimer’s LINX™️ offers a revolutionary change to the treatment of AD, facilitating far earlier diagnosis and innovatively widening the scope of AD testing to include previously unconsidered (but vitally important) environmental & immunological factors.
Alzheimer’s LINX™: The Early Advantage
Orthodox tests for AD usually only allow diagnosis at the point that significant mental decline & brain damage have already occurred. Alzheimer’s LINX™ changes the game by facilitating early detection in a way that has never been achieved before, enabling the more impactful treatment, and potentially even offering the opportunity to intervene before any damage has occurred.
Developed by leading immunologist Dr. Aristo Vodjani (often referred to as the father of functional immunology), and involving many years of medical research & testing, Alzheimer’s LINX™ tests strong serum immunoglobulin G (IgG) biomarkers for AD alongside brain protein antibodies (e.g., amyloid-beta peptide) and biomarkers (e.g., brain-derived neurotrophic factor – BDNF)) to ascertain markers of AD and to understand how effectively a patient might be able to recover from brain tissue degeneration.
Alzheimer’s LINX™: An Innovation in AD Testing
Alzheimer’s LINX™️, a strategically planned panel of biomarkers, reveals never-before-seen clinical perspectives of brain-related immune reactivity, providing invaluable insight into the diagnosis of AD at an early stage, including the
- Early detection of vulnerability to AD
- Early detection of indicators that indicate a heightened risk for developing AD
- Early detection of reactivity to triggers of AD
- Early-stage detection of neurodegeneration
- Identification of a complex lifestyle intervention strategy, where necessary.
- Enablement of monitoring of the effectiveness of lifestyle modifications in managing AD.
Alzheimer’s LINX™ also measures antibodies in a patient’s blood against specific environmental toxins – a hugely valuable insight into the patients’ immunological response. Identification of the potential cross-reactivity between food protein IgG and amyloid-beta peptide, for example, reveals reactive food antigens (e.g., non-gluten wheat proteins) that might (according to the sensitivity of that individual patient) play a significant role in the build-up of amyloid plaque in the brain.
Alzheimer’s LINX™ also focuses on the key role of gut health, and the health & permeability of the Blood-Brain Barrier (BBB) in AD, alongside the identification of different pathogens (such as herpes simplex virus-1, or Chlamydia pneumonia) or metals (e.g., mercury).
Testing of the health & permeability of the BBB is crucial because it acts as a gatekeeper for the brain, preventing the entry of potentially damaging autoreactive agents that are circulating in the bloodstream. A damaged, permeable BBB has been recognized as a risk factor in MCI (mild cognitive impairment, often a precursor to AD) and in the early stages of AD, because when these autoreactive agents cross the BBB into the brain, a reaction with amyloid-beta peptide can stimulate an immune reactivity response that can lead to the formation of brain plaque. Identifying their presence, as well as the permeability & overall health of the BBB, therefore remain key foci of the Alzheimer’s LINX™ test.
Alzheimer’s LINX™ tests across seven distinct categories of key contributory AD factors:
- BRAIN PROTEINS: Assessing reactivity to brain proteins beyond amyloid-beta and tau protein
- GROWTH FACTORS: Measuring immune reactivity to factors involved in neuronal regeneration
- ENTERIC NERVE, ENZYMES, AND NEUROLOGICAL PEPTIDES to assess immune reactivity to the communication pathway between the gut and the brain
- PATHOGENS, the immune reactivity of which is known to cross-react with amyloid-beta
- CHEMICALS: biomarkers used to measure chemicals/heavy metals in the body that are known to be associated with AD
- FOODS CROSS-REACTIVE TO AMYLOID BETA: Identification of common foods, newly discovered to have a potential association with AD
- BLOOD-BRAIN BARRIER AND NEUROFILAMENTS: Blood-Brain Barrier antibody biomarkers, used to assess the integrity of the blood-brain barrier
Alzheimer’s LINX also tests almost 40 biomarkers, including:
• Brand new Blood-Brain Barrier (BBB) antibody biomarkers
• New biomarker to test immune reactivity to Amyloid-Beta
• The eight most cross-reactive foods (out of 208 studied) newly discovered to have a potential association with AD
• New protein biomarkers that reveal immune reactivity and cross-reactivity to key brain cells and neurons at the heart of AD
• New oral bacterial biomarker that has shown to be associated with AD
• Biomarkers for a collection of chemicals and metals discovered to have associations to AD
• Performed on the Gold Standard ELISA platform, the most reliable lab technology on the market
Who Should Use Alzheimer’s LINX™?
Whilst everybody could benefit from early screening for AD, it is most strongly recommended for people who:
- Are interested in preventing the development of Alzheimer’s disease or other neurological disorders.
- Are exhibiting early signs of Alzheimer’s disease or other neurological disorders.
- Have been diagnosed with Alzheimer’s disease.
- Have a history of gastrointestinal disorders and/or diabetes.
- Played high-impact sports (because of the potential role of CTE (Chronic Traumatic Encephalopathy – repeated head trauma) – in sports.
- Are immunoreactive against specific pathogens, chemicals, and foods.
If you feel like you might be headed for trouble, let the Doctors Studio help you change course and take control of your cognitive health. We’re ready to talk you through the benefits of the Alzheimer’s LINX™ test and to ascertain whether it is a great treatment choice for you or someone you love.
You can not fix a problem you don’t understand. Advanced diagnostics is often necessary to get at the root cause. Once the root cause is identified, the solution becomes possible.
Don’t Know Where to Start?
The Studio Team is here to serve you.